REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Cited by (524)

Items 501–524 of 524

1. Nonclinical development of monovalent and polyvalent biopharmaceuticals
   Karin Staflin, Chandrashekhar K. Korgaonkar, Padma Kumar Narayanan, Rodney A. Prell, Donna W. Lee, Wendy Halpern, Anu V. Connor · 2024 · Elsevier eBooks
2. Treatment of COVID-19 with casirivimab/indevimab in a patient with cervical spine injury: A case report
   Miljana Vrhovac, Tijana Stanišić, Milan Mirković, Jelena Veličković, Sead Dalifi, Danilo Jeremić, Filip Pilipović, Tatjana Adžić‐Vukičević · 2025 · Srpski medicinski casopis Lekarske komore
3. Exploring SARS-CoV-2 Spike RBD Pockets as Targets for Generic Drugs: A Combined Computational, Biophysical, and Biological Approach
   Javier García‐Marín, Clara Francés‐Gómez, Alicia Forcada‐Nadal, Anmol S. Adhav, Clara Marco‐Marín, Vicente Rubio, Alberto Marina, J.L. Llacer, Ron Geller, Sonsoles Martín‐Santamaría · 2025 · ACS Omega
4. Study of audiological profile for covid 19 patients
   Doaa Mohamed Elmoazen, Hanan Mohamed AbdAlal AbdAlal, Alia Abdel Rahman Elkaraksy · 2025 · The Egyptian Journal of Otolaryngology
5. Additional file 1 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor
   Liu, Jinbiao, Brittany H. Bodnar, Meng, Fengzhen, Khan, Adil I., Wang, Xu, Sami Saribas, Wang, Tao, Saroj Chandra Lohani, Wang, Peng, Wei, Zhengyu et al. · 2021 · Figshare
6. Additional file 1 of Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes
   Seyed Mostafa Mostafavi Zadeh, Bayat, Ali Ahmad, Hosein Shahsavarani, Feridoun Karimi‐Busheri, Jafar Kiani, Roya Ghods, Zahra Madjd · 2024 · Figshare
7. Additional file 1 of Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
   Huang, Li, Che Zhang, Zhou, Xihui, Zhao, Zhou, Wang, Weiping, Leng, Weidong, Su, Xiao, Lian, Qizhou · 2021 · Figshare
8. Additional file 1 of Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
   Yalan, Qin, Hao Lingfang, Liu Xisong, Run, Liang, Junjing, Zhang, An, Zhang’ · 2024 · Figshare
9. Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
   Monika Kumari, Lu, Ruei-Min, Li, Mu-Chun, Jhih‐Liang Huang, Hsu, Fu-Fei, Ko, Shih-Han, Ke, Feng-Yi, Su, Shih-Chieh, Liang, Kang-Hao, Joyce Pei‐Yi Yuan et al. · 2022 · Figshare
10. Additional file 2 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor
    Liu, Jinbiao, Brittany H. Bodnar, Meng, Fengzhen, Khan, Adil I., Wang, Xu, Sami Saribas, Wang, Tao, Saroj Chandra Lohani, Wang, Peng, Wei, Zhengyu et al. · 2021 · Figshare
11. Sourcing and screening human antibody repertoires for discovering biotherapeutics
    Yasmina Noubia Abdiche, René Hoet · 2025 · Elsevier eBooks
12. Exposure route drives SARS-CoV-2 infection patterns in non-human primates
    Celine E. Snedden, Dylan H. Morris, T. C. Friedrich, J. O. Lloyd-Smith · 2026 · bioRxiv
13. Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes
    Yuelin Wang, Wei Dou, Yingying Chen, Ke Liu, Mengjun Li, Tyuji Hoshino, Yushan Jiang, Vladislav Victorovich Khrustalev, Alexey Viktorovich Churov, Alexander N. Orekhov et al. · 2026 · Virologica Sinica
14. Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
    Jérémy Dufloo · 2021 · theses.fr (ABES)
15. Selection of Functional Glycoforms in Anti-SARS-CoV-2 Human IgG1 Monoclonal Antibodies by FcγRIIIa Affinity Chromatography and Mass Spectrometry
    Barbara Oliviero, Sunil Kumar, Daniela Conteianni, Gaia Donetti, Antonella Cerino, Antonino Samuele Iraci, Alessia La Gaipa, Sabrina Ottolini, Sara Tengattini, Gabriella Massolini et al. · 2026 · Journal of Medicinal Chemistry
16. Étude des mécanismes d’action de nouveaux inhibiteurs de coronavirus humains
    Thomas Meunier · 2021
17. Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants
    Jesper Pallesen, Jianqiu Du, Yuanhan Wu, Sukanya Ghosh, Kelly Bayruns, Roopak Sadeesh, David B. Weiner · 2026 · Research Square
18. Enteric α-defensins contribute to intestinal mucosal immunity against SARS-CoV-2 infection
    Yilin Yang, 杨倩曦, Xin Huang, Chongbing Liao, Zhenguo Chen, Wuyuan Lu · 2026 · Mucosal Immunology
19. A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model
    Ming Zhou, Xuan Liu, Jinxin Miao, Yanzhen Lin, Haiqing Xiao, Kun Wu, Longmei Zhang, Xinglin Li, Xinyi Yang, Lin Chen et al. · 2026 · Molecular Biomedicine
20. Pangolin-derived sarbecoviruses show attenuated pathogenicity and transmissibility compared with SARS-CoV-2 in human ACE2 transgenic hamsters
    Haofeng Lin, Ren-Di Jiang, Li-Na Ji, Jin-Wei Zhang, Qian-Chun Gong, Hao-Rui Si, Yuan-Sen Shi, Xinhua Lin, Chen Qiu, Jianmin Li et al. · 2026 · mBio
21. Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus
    Celine E. Snedden, Dylan H. Morris, Thomas C. Friedrich, James O. Lloyd‐Smith · 2026 · Science Advances
22. Crystal structures of SARS-CoV-2 main protease and its complex with PBI-0451
    Haihai Jiang, Wenwen Li, Jin Zhang, Jian Li · 2026 · Acta Crystallographica Section D Structural Biology
23. Kinetics of immunological memory to SARS-CoV-2
    Shane Crotty, Alessandro Sette, Daniela Weiskopf · 2022 · ImmPort
24. Summary
    Shane Crotty, Alessandro Sette, Daniela Weiskopf · 2022 · ImmPort